Acura Pharmaceuticals is engaged in the development and commercialization of abuse-deterrent products... Read more
Acura Pharmaceuticals is engaged in the development and commercialization of abuse-deterrent products... Read more
News
Jul 26, 2024
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : New Financial Obligation Form 8 K
Dec 21, 2023
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K
Aug 16, 2023
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K
Jun 30, 2023
Marketscreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
Jun 28, 2023
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K
Jun 27, 2022
BizPlus
Acura Pharmaceuticals Inc: Peak Technologies acquires VisionID from Robert Jones
Mar 01, 2022
FirstWord Pharma
Acura Pharmaceuticals Inc: Acura Pharmaceuticals and AD Pharma Amend License to LIMITx LTX-03
Feb 15, 2022
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : Provides Development Update on LTX-03 - Form 8-K
Dec 28, 2021
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : NEGOTIABLE PROMISSORY NOTE - Form 8-K
Nov 18, 2021
MarketScreener
Acura Pharmaceuticals Inc: Acura Pharmaceuticals : Announces Third Quarter 2021 Financial Results - Form 8-K
Acura Pharmaceuticals Inc Competitors
1
2
3
4
5
6
7
8
9
10